Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Athanasios Galanopoulos, MD PhD, Evdoxia Kamouza, Christos K. Kontos, PhD, Argiris Symeonidis, MD PhD, Vassiliki Pappa, MD, Alexandra Kourakli, MD PhD, Nora-Athina Viniou, MD, Sotirios Papageorgiou, MD PhD, Charalampos Pontikoglou, Menelaos Konstantinos Papoutselis, Helen A. Papadaki, MD PhD, Eleftheria Hatzimichael, Panagiotis Zikos, Dr, Maria Dimou, Panayiotis Panayiotidis, MD PhD, Dimitrios Tsokanas, Despina Mparmparousi, Flora Kontopidou, Eleni Variami, Panagiotis Repousis, MD, Elias Poulakidas, Dimitrios Christoulas, MD, Theodoros Vassilakopoulos, MDPhD, Michael Voulgarelis, MD PhD, Aikaterini Megalakaki, Maria Kotsopoulou, Giorgos Karianakis, Despina Kaliontzi, Ioannis Adamopoulos, MD, Maria Dalekou, Anastasia Sioni, Maria Papaioannou, Dimitrios Gogos, Panagiotis Theodorou Diamantopoulos, MD PhD, Elena E. Solomou, MD, Ioannis Kotsianidis, PhD

Blood (2018) 132 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2018-99-119531

Published: 2018

Journal Articles

Downregulation of the Tumor Suppressor SAMHD1 in Classical Hodgkin Lymphoma

Ioanna Xagoraris, MD, Theodoros Vassilakopoulos, MDPhD, Nikolas Herold, MDPhD, Nikolaos Tsesmetzis, MSc., Elias Drakos, MD PhD, Joseph David Khoury, MD, George Rassidakis, MD PhD

Blood (2017) 130 (Supplement 1): 1480.

https://doi.org/10.1182/blood.V130.Suppl_1.1480.1480

Published: 2017

Journal Articles

Bone Marrow Levels of PARP1 mRNA Predict Response to Treatment with 5-Azacytidine in Patients with Myelodysplastic Syndrome

Panagiotis Theodorou Diamantopoulos, MD PhD, Elina Kodandreopoulou, Argiris S. Symeonidis, Ioannis Kotsianidis, MDPhD, Vassiliki Pappa, MDPhD, Athanasios Galanopoulos, MD PhD, Maria Dimou, Georgia Christopoulou, Konstantinos Zervakis, Elena E. Solomou, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Niki Rougala, Marina Siakantaris, MD, Theodoros Vassilakopoulos, MDPhD, Panayiotis Panayiotidis, MDPhD, Nora-Athina Viniou

Blood (2017) 130 (Supplement 1): 161.

https://doi.org/10.1182/blood.V130.Suppl_1.161.161

Published: 2017

Journal Articles

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Ioannis Kotsianidis, MD PhD, Sotirios Papageorgiou, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Nora-Athina Viniou, Alexandra Kourakli, Theodoros Vassilakopoulos, MDPhD, Menelaos Konstantinos Papoutselis, Zoi Topouzoglou, Panagiotis Theodorou Diamantopoulos, MD PhD, Dimitrios Τsokanas, Argiris Symeonidis, MD PhD

Blood (2017) 130 (Supplement 1): 4251.

https://doi.org/10.1182/blood.V130.Suppl_1.4251.4251

Published: 2017

Journal Articles

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

Argiris Symeonidis, MD PhD, Alexandra Kourakli, MD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, Eleftheria Hatzimichael, Theodoros Vassilakopoulos, MDPhD, Aikaterini Palla, Vassiliki Pappa, MD, Evgenia Verigou, Zafeirios Kartasis, MD, Eirini Katodritou, Maria Pagoni, Theodora Assimakopoulou, Charalampos Pontikoglou, MD PhD, Maria Dimou, George Xanthopoulidis, Maria K. Angelopoulou, MD, Maria Kotsopoulou, Dimitra Liapi, Despina Mparmparousi, Evridiki Michali, Anna Kioumi, Nora-Athina Viniou, Achilles Anagnostopoulos, Vassiliki Labropoulou, Maria Dalekou, Michael Voulgarelis, MD PhD, Efthymia Vlachaki, Anna Christoforidou, Ioannis Adamopoulos, MD, Akrivi Kostourou, Petros Laos, Evangelos Terpos, MD PhD, Eleni Kapsali, George Vassilopoulos, MD PhD, Helen A. Papadaki, MD PhD, Panayiotis Panayiotidis, MD PhD, Athanasios Galanopoulos, MD PhD

Blood (2017) 130 (Supplement 1): 1696.

https://doi.org/10.1182/blood.V130.Suppl_1.1696.1696

Published: 2017

NARROW

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Downregulation of the Tumor Suppressor SAMHD1 in Classical Hodgkin Lymphoma

Bone Marrow Levels of PARP1 mRNA Predict Response to Treatment with 5-Azacytidine in Patients with Myelodysplastic Syndrome

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

Email alerts

ASH Publications

American Society of Hematology

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Downregulation of the Tumor Suppressor SAMHD1 in Classical Hodgkin Lymphoma

Bone Marrow Levels of PARP1 mRNA Predict Response to Treatment with 5-Azacytidine in Patients with Myelodysplastic Syndrome

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only